Diagnostic and Prognostic Model of Pulmonary Fibrosis After COVID-19 Pneumonia and Mechanism Study
NCT ID: NCT05719038
Last Updated: 2023-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2023-01-30
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
NCT04987528
Disease-syndrome Characteristics of IPF
NCT07178392
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
NCT05895409
Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China
NCT06655090
Pulmonary Fibrosis After Severe COVID-19 Pneumonia
NCT06423560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy control group
observational study
observational study
Pulmonary fibrosis after COVID-19 Pneumonia
observational study
observational study
No pulmonary fibrosis after COVID-19 Pneumonia
observational study
observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
observational study
observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. novel coronavirus nucleic acid or antigen confirmed novel coronavirus infection
3. Meet the diagnostic criteria for moderate/severe/severe coronavirus infection in China (Trial Tenth Edition)
4. Chest CT showed that the extent of lung lesions was greater than 50%
Exclusion Criteria
2. previous severe lung disease, such as known chronic lung disease: chronic obstructive pulmonary disease, asthma, interstitial lung disease, etc.
3. severe organ dysfunction: severe liver, kidney and heart dysfunction
4. severe epidemic defects (including tumors/severe rheumatism/organs, bone marrow transplantation/HIV, etc.)
5. inappropriate enrollment judged by the investigator
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kunming Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yuqi Cheng
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Xue M, Zhang T, Chen H, Zeng Y, Lin R, Zhen Y, Li N, Huang Z, Hu H, Zhou L, Wang H, Zhang XD, Sun B. Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients. Int J Biol Sci. 2021 Apr 10;17(6):1565-1573. doi: 10.7150/ijbs.58825. eCollection 2021.
Li X, Shen C, Wang L, Majumder S, Zhang D, Deen MJ, Li Y, Qing L, Zhang Y, Chen C, Zou R, Lan J, Huang L, Peng C, Zeng L, Liang Y, Cao M, Yang Y, Yang M, Tan G, Tang S, Liu L, Yuan J, Liu Y. Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: a cohort study. Respir Res. 2021 Jul 9;22(1):203. doi: 10.1186/s12931-021-01798-6.
Yang J, Chen C, Chen W, Huang L, Fu Z, Ye K, Lv L, Nong Z, Zhou X, Lu W, Zhong M. Proteomics and metabonomics analyses of Covid-19 complications in patients with pulmonary fibrosis. Sci Rep. 2021 Jul 16;11(1):14601. doi: 10.1038/s41598-021-94256-8.
Sardar R, Sharma A, Gupta D. Machine Learning Assisted Prediction of Prognostic Biomarkers Associated With COVID-19, Using Clinical and Proteomics Data. Front Genet. 2021 May 20;12:636441. doi: 10.3389/fgene.2021.636441. eCollection 2021.
Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung Fibrosis after COVID-19: Treatment Prospects. Pharmaceuticals (Basel). 2021 Aug 17;14(8):807. doi: 10.3390/ph14080807.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KunmingMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.